Modulation of the transcription of pro-inflammatory gene products
CA 2424604 A1 · Owner: Hecker, Markus · Inventors: Hecker, Markus; Wagner, Andreas H.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to inhibitors of the transcription factor IRF-1 the use , thereof as a therapeutical agent and to the use thereof for the prevention or the therapy of cardiovascular complications such as restenosis following percutaneous angioplasty or stenosis of venous bypasses chronic (transplant , arteriosclerosis or vasculopathy) or acute graft rejection graft versus host , disease (GVHD), immunological hypersensitivities (allergies) especially , asthma bronchiale and atopic dermatitis chronic recurrent inflammatory , diseases especially colitis ulcerosa and Crohn's disease psoriasis and , sarcoidosis, as well as autoimmune diseases especially diabetes mellitus, multiple …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 4, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 4, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 4, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.